Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · IEX Real-Time Price · USD
7.92
+0.08 (0.96%)
At close: May 17, 2024, 4:00 PM
8.20
+0.28 (3.60%)
After-hours: May 17, 2024, 5:36 PM EDT
Company Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.
The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
Shattuck Labs, Inc. was incorporated in 2016 and is headquartered in Austin, Texas.
Shattuck Labs, Inc.
Country | United States |
Founded | 2016 |
IPO Date | Oct 9, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 75 |
CEO | Dr. Taylor H. Schreiber M.D., Ph.D. |
Contact Details
Address: 500 W. 5th Street Austin, Texas 78701 United States | |
Phone | 512-900-4690 |
Website | shattucklabs.com |
Stock Details
Ticker Symbol | STTK |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $17.00 |
CIK Code | 0001680367 |
CUSIP Number | 82024L103 |
ISIN Number | US82024L1035 |
Employer ID | 81-2575858 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Taylor H. Schreiber M.D., Ph.D. | Co-Founder, Chief Executive Officer and Director |
Dr. Abhinav A. Shukla Ph.D. | Chief Technical Officer |
Dr. Arundathy Nirmalini Pandite M.B.A., M.D. | Chief Medical Officer |
Andrew R. Neill M.B.A. | Chief Financial Officer |
Conor Richardson CPA | Vice President of Investor Relations |
Dr. Stephen Stout J.D., Ph.D. | General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer |
Casi DeYoung | Chief Business Officer |
Dr. Thomas Lampkin Pharm.D. | Senior Vice President of Regulatory Affairs |
George Fromm Ph.D. | Chief Scientific Officer of ARC Platform |
Suresh de Silva Ph.D. | Chief Scientific Officer of GADLEN Platform |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 2, 2024 | 10-Q | Quarterly Report |
May 2, 2024 | 8-K | Current Report |
Apr 23, 2024 | ARS | Filing |
Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
Mar 6, 2024 | 144 | Filing |
Mar 4, 2024 | 8-K | Current Report |
Feb 29, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 29, 2024 | 10-K | Annual Report |
Feb 29, 2024 | 8-K | Current Report |